Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma

Cancer

Volumn 107, Issue 7, 2006, Pages 1530-1541

  Grann, Victor R ^a,b,c,g   Hershman, Dawn ^a,b,c   Jacobson, Judith S ^b   Tsai, Wei Yann ^b   Wang, Jian ^b   McBride, Russell ^b   Mitra, Nandita ^d   Grossbard, Michael L ^e,f   Neugut, Alfred I ^a,b,c  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b Department of Medicine   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Institute for Head and Neck and Thyroid Cancer   (United States)

^f ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^g Department of Medicine   (United States)

Author keywords

Cardiotoxicity; Doxorubicin; Elderly; End Results Medicare data base; Epidemiology; Non Hodgkin lymphoma; Radiation therapy; Surveillance

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL TIME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33749590629     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22188     Document Type: Article

References (36)

1. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program. 2004:221-236.
2. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484-1493.
3. Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992;327:1342-1349.
4. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
5. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. 2002;29(2 Suppl 6):18-22.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
7. Ries L, Eisner M, Kosary C, et al. SEER cancer statistics review, 1975-2002, vol 2005. Bethesda: National Cancer Institute, 2005. Available at URL: http://seer.cancer.gov/csr/1975_2002/ [based on the November 2004 SEER data submission, posted to the SEER web site 2005]. Accessed December 14, 2005.
8. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302-4311.
9. Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer. 1991;67:2633-2641.
10. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA. 1987;257:2766-2770.
11. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
12. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136:349-357.
13. Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002;20:173-178.
14. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21:3409-3414.
15. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40(8 Suppl):IV-19-25.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
17. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV-55-IV-61.
18. Lament EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002;40:201-211.
19. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
20. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 Pt 2):757-763.
21. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968;24:295-313.
22. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998;54:948-963.
23. Mitra N, Heitjan DF. Sensitivity of the Hazard Ratio to Non-Ignorable Treatment Assignment in an Observational Study. Upenn Biostatistics Working Papers. Paper 5, 2006. The Berkeley Electronic Press. Available at: http://biostats/bepress.com/upennbiostat/papers/arts [accessed May 24, 2006].
24. Cheson BD. CHOP plus rituximab-balancing facts and opinion. N Engl J Med. 2002;346:280-292.
25. Grann A, Grann VR. The case for randomized trials in cancer treatment: new is not always better. JAMA. 2005;293:1001-1003.
26. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530-2539.
27. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-4126.
28. Miller TP, Dana BW, Weick JK, et al. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1988;25(2 Suppl 2):17-22.
29. Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA Jr. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1987;24(2 Suppl 1):21-25.
30. Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-75-81.
31. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
32. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106:3183-3190.
33. Steyerberg EW, Earle CC, Neville BA, Weeks JC. Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2005;23:510-517.
34. Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20:2643-2650.
35. Hershman D, Jacobson JS, McBride R, et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol. 2004;94:540-549.
36. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology - v.2.2006 Non-Hodgkin's Lymphoma. Available at: http://www.nccn.org/ professionals/physicians_gls/PDF/nhl.pdf [accessed May 24, 2006].